Australia’s experience of lurbinectedin for patients with advanced refractory small cell lung cancer (SCLC) is similar to that reported in clinical trials, providing reassurances of real-world efficacy and toxicities, researchers say.
The synthetic alkaloid is a selective inhibitor of oncogenic transcription, which received provisional approval for use in Australia in 2021 under the brand name Zepzelca.
To assess its use in Australia, a team at Peter Mac Cancer Centre, Melbourne, analysed real-world data from 46 patients with small cell lung cancer (SCLC) initiating lurbinectedin monotherapy (3.2 mg/m2 three-weekly) across seven sites as part of an early access program in Australia between May 2020 and December 2021.
All patients (median age 67, 57% female) had extensive stage disease by the time of lurbinectedin initiation, most of which involved two or more metastatic sites of disease (72%); mostly bone (48%), liver (46%), lung (46%) and brain (39%).
The novel oncogenic transcription inhibitor was given as a second- (83%) or subsequent- (17%) line therapy, mostly with prior chemoimmunotherapy (87%), said the study authors.
All patients received first-line platinum doublet therapy (96% carboplatin), with the majority in combination with ICI (atezolizumab (n = 35); durvalumab (n = 2)).
Only two individuals were alive at data cutoff and both had discontinued lurbinectedin, one because of toxicity and the other because of progression.
The median duration of therapy was 64 days and half of the cohort received three or fewer cycles of lurbinectedin.
Writing in the Internal Medicine Journal [link here], the researchers said dose modifications (17%) and interruptions/delays (24%) were common, while there were also high-grade toxicities (28%) and hospitalisations (54%) during treatment.
Almost half of the hospitalisations were related to lurbinectedin.
The overall response rate was 33% and the disease control rate was 50%. For second and subsequent lines, the overall response rate was 26% and 56%, respectively.